SASTASUNDR
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
Get instant stock alerts
-
Share Price
-
Financials
-
Revenue mix
-
Shareholdings
-
Peers
-
Forensics
Coming soon
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
| (In Cr.) |
|---|
| (In Cr.) | ||||
|---|---|---|---|---|
|
This data is currently unavailable for this company. |
| (In %) |
|---|
| (In Cr.) |
|---|
| Financial Year (In Cr.) |
|---|
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Recent events
-
News
-
Corporate Actions
India's Sastasundar Ventures gains on Q1 profit climb
** Shares of Sastasundar Ventures SAST.NS climb 8% to 337.90 rupees
** SAST's Q1 consol net profit shot up ~24x helped by a deferred tax gain
** Excluding the gain, profit climbed 24% Y/Y
** Stock, however, down ~18% YTD after gaining 46% in 2023
(Reporting by Kashish Tandon in Bengaluru)
** Shares of Sastasundar Ventures SAST.NS climb 8% to 337.90 rupees
** SAST's Q1 consol net profit shot up ~24x helped by a deferred tax gain
** Excluding the gain, profit climbed 24% Y/Y
** Stock, however, down ~18% YTD after gaining 46% in 2023
(Reporting by Kashish Tandon in Bengaluru)
Sastasundar Ventures June-Quarter Consol Net Profit At 311.5 Mln Rupees
July 29 (Reuters) - Sastasundar Ventures Ltd SAST.NS:
JUNE-QUARTER CONSOL NET PROFIT 311.5 MILLION RUPEES
JUNE-QUARTER CONSOL TOTAL REVENUE FROM OPERATIONS 2.7 BILLION RUPEES
Source text for Eikon: ID:nNSE3smfqD
Further company coverage: SAST.NS
(([email protected];))
July 29 (Reuters) - Sastasundar Ventures Ltd SAST.NS:
JUNE-QUARTER CONSOL NET PROFIT 311.5 MILLION RUPEES
JUNE-QUARTER CONSOL TOTAL REVENUE FROM OPERATIONS 2.7 BILLION RUPEES
Source text for Eikon: ID:nNSE3smfqD
Further company coverage: SAST.NS
(([email protected];))
Sastasundar Ventures Ltd- Re-Appointment Of Banwari Lal Mittal As MD & CEO
Sastasundar Ventures Ltd SAST.NS:
SASTASUNDAR VENTURES LTD- RE-APPOINTMENT OF BANWARI LAL MITTAL AS MD & CEO
Source text for Eikon: ID:nBSE1W8bdq
Further company coverage: SAST.NS
Sastasundar Ventures Ltd SAST.NS:
SASTASUNDAR VENTURES LTD- RE-APPOINTMENT OF BANWARI LAL MITTAL AS MD & CEO
Source text for Eikon: ID:nBSE1W8bdq
Further company coverage: SAST.NS
Events:
More Micro Cap Ideas
See similar 'Micro' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
-
Business
-
Financials
-
Share Price
-
Shareholdings
What does Health X Platform do?
Health X Platform is creating a Digital Network of Healthcare to optimize Pharma Supply Chain, connect healthcare services, clinics, and provide health information. They use an online to offline model with physical service centers for personalized pharmacist counseling.
Who are the competitors of Health X Platform?
Health X Platform major competitors are Max India, Amrutanjan Healthcar, Rajnish Wellness, Jeena Sikho Life, Medplus Health Servi, Cupid, 3B Blackbio Dx. Market Cap of Health X Platform is ₹898 Crs. While the median market cap of its peers are ₹1,715 Crs.
Is Health X Platform financially stable compared to its competitors?
Health X Platform seems to be less financially stable compared to its competitors. Altman Z score of Health X Platform is 4.02 and is ranked 7 out of its 8 competitors.
Does Health X Platform pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Health X Platform latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%
How strong is Health X Platform balance sheet?
The companies balance sheet of Health X Platform is weak, but was strong historically.
Is the profitablity of Health X Platform improving?
The profit is oscillating. The profit of Health X Platform is ₹29.09 Crs for TTM, -₹91.17 Crs for Mar 2025 and ₹8.88 Crs for Mar 2024.
Is Health X Platform stock expensive?
Health X Platform is expensive when considering the PE ratio, however latest Price to Book is < 3 yr avg Price to Book. Latest PE of Health X Platform is 33.44 while 3 year average PE is 6.97. Also latest Price to Book of Health X Platform is 1.28 while 3yr average is 1.9.
Has the share price of Health X Platform grown faster than its competition?
Health X Platform has given lower returns compared to its competitors. Health X Platform has grown at ~0.94% over the last 3yrs while peers have grown at a median rate of 22.96%
Is the promoter bullish about Health X Platform?
Promoters seem to be bullish about the company. Latest quarter promoter holding is 74.69% and last quarter promoter holding is 74.24%.
Are mutual funds buying/selling Health X Platform?
There is Insufficient data to gauge this.
